Sandoz - A Global Leader
Nick Haggar
March 2013

Head Sandoz Africa, Middle East and
Western Europe
Sandoz a Global Leader
This is the first dummy chapter

2 | Together Growing Faster - Sandoz and Celesio | October 10 th, ...
Sandoz is a Novartis Group Company
Environment

Patient needs

Novartis portfolio

Innovative
medicines

2011 sales
USD bi...
Novartis’ mission is to care for and cure patients

In 2011, Novartis treated and protected more than
1 billion patients
a...
Sandoz is a global leader in generics
2011 generics sales1
USD million
10,196
9,473
5,559
3,320
2,432
2,358

 Present in ...
Sandoz operates in 140 countries globally
Development*
Production*

Unterach

Holzkirchen

Barleben

Rudolstadt

Subsidiar...
Sandoz has an industry-leading
breadth of technologies
Biosimilars

Lyophilization

Ophthalmics

Patches/
transdermals/
th...
Anti-Infectives: Sandoz is the leading Gx player
Total anti-infectives sales
USD bn (FY 2011)
Pfizer

3.7

CAGR1
Percent (...
Sandoz in first dummy chapter
This is the Africa
Commitment and Growth in Africa
World Economic Forum, Addis Ababa
Wide range of bilateral meetings
•4 Ministers
•7 NGOs (B...
5 joint projects to improve patient’s life Zambia Example
Health shops

Cardiovascular Academy

Build high quality,
afford...
Focus Areas

Quality
Regulatory
Distribution
Affordability
Partnerships
REGIONAL FOCUS: GROWTH
OPPORTUNITIES FOR PHARMA COMPANIES
IN THE WEST AFRICAN MARKET
DR YAW ADU GYAMFI, CEO, DANADAMS PHAR...
Upcoming SlideShare
Loading in...5
×

Sandoz in Africa - a global leader

640

Published on

Presentation by Sandoz made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
640
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
23
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Sandoz in Africa - a global leader

  1. 1. Sandoz - A Global Leader Nick Haggar March 2013 Head Sandoz Africa, Middle East and Western Europe
  2. 2. Sandoz a Global Leader This is the first dummy chapter 2 | Together Growing Faster - Sandoz and Celesio | October 10 th, 2012
  3. 3. Sandoz is a Novartis Group Company Environment Patient needs Novartis portfolio Innovative medicines 2011 sales USD billion Pharmaceuticals 32.5 Eye Care (Alcon, CIBA VISION) 10.0 Sandoz – Generics 9.5 Self-care Consumer Health (OTC, Animal Health) 4.6 Prevention Vaccines and Diagnostics 2.0 Affordable options Full range of healthcare options
  4. 4. Novartis’ mission is to care for and cure patients In 2011, Novartis treated and protected more than 1 billion patients around the world with our products and Sandoz medicines reached over 400 million patients
  5. 5. Sandoz is a global leader in generics 2011 generics sales1 USD million 10,196 9,473 5,559 3,320 2,432 2,358  Present in 140 countries  ~25,000 employees worldwide  Portfolio of ~1,100 compounds and >23,500 SKUs 2,313  Rich pipeline with >800 projects 2,273  Leader in differentiated generics 2,126  Biosimilars pioneer 1,876 Pro forma by including all acquired companies Note: Figures reflect sales and ROS for generics business only, including API and excluding originator (e.g. Copaxone) and proprietary business (e.g. Women’s Health) Note: All trademarks, logos and pictures are the property of the respective owner Source: Company annual and quarterly reports, except Actavis figures estimated based on IMS 1
  6. 6. Sandoz operates in 140 countries globally Development* Production* Unterach Holzkirchen Barleben Rudolstadt Subsidiaries Representative offices Boucherville Strykow Wilson Kundl / Schaftenau Ljubljana / Mengeš Broomfield Candelaria Kaminoyama Cambe/ Taboao Zhongshan Buenos Aires Gebze * Sample Sandoz manufacturing and development sites. Spartan Turbhe Kalwe Jakarta
  7. 7. Sandoz has an industry-leading breadth of technologies Biosimilars Lyophilization Ophthalmics Patches/ transdermals/ thin films Hormones Injectables Inhalers Cytotoxics API Innovative solid formulations Implants Dermatology
  8. 8. Anti-Infectives: Sandoz is the leading Gx player Total anti-infectives sales USD bn (FY 2011) Pfizer 3.7 CAGR1 Percent (200911) -6% GlaxoSmithKline 1.7 -4% Sandoz 1.7 +4% Sanofi 2 1.3 -5% Teva 1.3 -8% Merck & Co. 1.2 -12% Johnson & Johnson 1.0 -25% Daiichi Sankyo 2 0.9 -5% Medicis 0.8 +22% Bayer 0.7 -2% 1 2 Growth rate at constant currency rate Incl. Generic business Source: IMS, global market, anti-infectives defined as J1 (antibacterials) Gx Originator
  9. 9. Sandoz in first dummy chapter This is the Africa
  10. 10. Commitment and Growth in Africa World Economic Forum, Addis Ababa Wide range of bilateral meetings •4 Ministers •7 NGOs (Bill & Melinda Gates Foundation, Director-General of Red Cross, ...) •Private companies (Philips, Coca Cola, Merck, ...) •Development organizations (GIZ, US African Development Foundation, ...) Minister of Industry and Trade, Egypt Minister of Health, Ethiopia AU-UNIDO Conference on Diversified Economy and Manufacturing, Addis Ababa of bilateral meetings Wide range •Local manufacturers from Ethiopia, Kenya, Botswana, Sierra Leone, ... •UN, WHO, GIZ, British Embassy, German Embassy, Swiss Embassy
  11. 11. 5 joint projects to improve patient’s life Zambia Example Health shops Cardiovascular Academy Build high quality, affordable portfolio Rheumatic Heart Disease Zambora Project
  12. 12. Focus Areas Quality Regulatory Distribution Affordability Partnerships
  13. 13. REGIONAL FOCUS: GROWTH OPPORTUNITIES FOR PHARMA COMPANIES IN THE WEST AFRICAN MARKET DR YAW ADU GYAMFI, CEO, DANADAMS PHARMACEUTICAL INDUSTRIES NICK HAGGAR, HEAD, WESTERN EUROPE, MIDDLE EAST & AFRICA, SANDOZ MODERATOR: DR VINCE S. THOMAS, MANAGING DIRECTOR, V.S THOMAS GLOBAL HEALTH STRATEGY CONSULTING
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×